Last updated: June 29, 2026
AuroMedics Pharma LLC v. Ingenus Pharmaceuticals, LLC (1:20-cv-01235) Litigation Summary and Patent Analysis
AuroMedics Pharma LLC sued Ingenus Pharmaceuticals, LLC in the Southern District of Indiana in case 1:20-cv-01235, alleging patent infringement tied to Abbreviated New Drug Application (ANDA) activity. The matter proceeds under the standard Hatch-Waxman framework for Orange Book-listed patents. The complaint is mapped to infringement contentions common to ANDA paragraph IV cases, but the substantive, claim-level patent details, asserted patent numbers, and case-specific orders are required to produce a complete, accurate litigation summary and enforceable analysis.
What is the status of AuroMedics Pharma LLC v. Ingenus Pharmaceuticals, LLC 1:20-cv-01235?
Status cannot be stated with precision from the information provided. A litigation summary that is fit for licensing, litigation, or investment decisions must identify the latest docket posture (e.g., motions to dismiss, claim construction, summary judgment, trial, settlement, consent judgment) and the dates of key rulings.
What docket milestones typically drive value in this case?
For ANDA patent suits like 1:20-cv-01235, the main value-bearing events usually include:
- service of complaint and answer
- motions (pleadings, venue, personal jurisdiction)
- Markman/claim construction schedule
- expert submissions and dispositive motions
- infringement and validity rulings
- any injunction or design-around outcomes
Which patents were asserted by AuroMedics in 1:20-cv-01235?
A complete litigation analysis requires the specific asserted patent numbers, their titles, the Orange Book listing context, and the infringement theories (direct, induced, contributory; method-of-use vs formulation vs device; product-by-process where applicable). That information is not provided.
What patent categories are usually asserted in ANDA cases like this?
Depending on the Orange Book composition for the reference listed drug, asserted patents often fall into:
- composition or formulation patents (dosage form composition, coatings, excipients, particle engineering)
- method-of-use patents (therapeutic regimen, dosing scheme, patient population)
- manufacturing process patents (granulation, milling, blending, sterilization)
- polymorph/crystal form patents (if relevant to the drug substance or solid form)
Without the actual asserted patents, no accurate mapping is possible.
What Orange Book patents cover the reference drug in AuroMedics v. Ingenus (1:20-cv-01235)?
An Orange Book status analysis must cite:
- the drug (RLD) name
- the application holder (NDA/BLA holder)
- the listed patents with their expiration dates and pediatric exclusivity impact
- any listed patent certifications tied to the ANDA
None of those items are available in the prompt.
How does the case framework work for an ANDA patent infringement suit like 1:20-cv-01235?
Even without the case-specific patent list, the procedural architecture for ANDA infringement actions is consistent:
Paragraph IV and the typical infringement posture
- The ANDA filer makes certification to listed patents in the Orange Book.
- If it files a Paragraph IV certification, the patent holder can sue within the statutory window.
- The lawsuit then tracks standard patent issues: infringement, invalidity (anticipation, obviousness, lack of written description/enablement, indefiniteness), and enforceability defenses.
Typical remedies at stake
- declaratory judgment on infringement and invalidity
- potential injunction under 35 U.S.C. § 271(e)(4)(A) if the ANDA is enjoined
- design-around or non-infringement findings affecting generic entry timing
What did AuroMedics allege about Ingenus’ ANDA product in 1:20-cv-01235?
A claim-level or even element-level allegations summary requires the complaint’s infringement contentions:
- which asserted claims
- what specific ANDA product design details are accused
- whether Ingenus’ Paragraph IV notice alleged facts about manufacturing or dosing
- whether the case hinges on formulation parameters, manufacturing steps, or clinical regimens
No complaint content is included.
What claims and theories were challenged in motions practice (infringement, invalidity, claim construction)?
A litigation analysis must cover:
- claim construction outcomes (critical to infringement and invalidity)
- summary judgment rulings
- trial issues if any
- evidentiary rulings affecting expert reliability and admissibility
No such docket rulings are provided.
Did the parties reach a settlement or consent judgment in AuroMedics v. Ingenus (1:20-cv-01235)?
A settlement analysis must specify:
- whether there was a settlement
- effective date and any agreed entry date
- any license terms, cross-licenses, or covenant-not-to-sue scope
- dismissal with or without prejudice and any covenants tied to specific patents
Settlement terms cannot be derived from the prompt.
What generic entry risks exist for Ingenus based on 1:20-cv-01235?
Generic entry risk depends on:
- whether AuroMedics asserted patents that are tied to the product’s exclusivity
- whether any patents were held invalid or not infringed
- whether injunctive relief was granted
- whether design-arounds were pursued successfully
No patent list or judgment posture is provided.
How strong is the patent estate in AuroMedics v. Ingenus (1:20-cv-01235)?
Patent strength analysis requires:
- validity vulnerabilities (prior art, claim scope, prosecution history)
- claim construction dependence
- any contemporaneous PTAB challenges (IPR/PGR) or reexamination
- enforceability issues (inequitable conduct, ownership standing)
None of these inputs are present.
Which comparable lawsuits or parallel filings affect the litigation strategy in 1:20-cv-01235?
Competitive and strategic assessment usually incorporates:
- parallel litigations against other ANDA filers
- co-pending ANDA suits tied to the same RLD patents
- licensing arrangements affecting market entry timing
No related case list is available.
Timeline of litigation events for 1:20-cv-01235
A precise timeline must use docket dates: filing, service, initial scheduling order, Markman deadlines, claim construction hearing, summary judgment deadlines, trial dates, and any final judgment/settlement dates.
No docket dates are provided.
Key Takeaways
- AuroMedics Pharma LLC sued Ingenus Pharmaceuticals, LLC in 1:20-cv-01235 under an ANDA patent infringement framework.
- A complete and accurate litigation summary cannot be produced from the provided information because it lacks the asserted patent numbers, Orange Book context, and docket outcomes.
- No defensible conclusions can be drawn on exclusivity exposure, injunction risk, validity, infringement strength, settlement status, or generic launch timing without the case-specific record.
FAQs
- What patents were asserted in AuroMedics Pharma LLC v. Ingenus Pharmaceuticals, LLC (1:20-cv-01235)?
- What did the court decide on claim construction in 1:20-cv-01235?
- Was there a Paragraph IV settlement or covenant-not-to-sue in 1:20-cv-01235?
- Which Orange Book patents and expirations controlled the market-entry timing in 1:20-cv-01235?
- Did the court grant or deny injunctive relief under 35 U.S.C. § 271(e)(4) in 1:20-cv-01235?
References (APA)
- Provided information only (no case docket text, complaint, orders, or Orange Book listings were included).
